Materialise: Maturing Transition Should Lead To Stronger Performance Going Forward

While Materialise's Q1 results were soft, its Medical segment appears to be stabilizing and the software business model transition is nearing completion. Cost discipline and a return to growth should see margins start to consistently move higher, assuming that the macro environment remains stable. Despite the stock moving higher in recent months, a material improvement in performance still isn't priced into the stock.

Materialise's (MTLS) share price has rebounded somewhat in recent months, despite the company reporting relatively soft results in the first quarter of 2026. Much of this weakness was due to foreign exchange headwinds, and the Manufacturing segment demonstrated signs of stabilization.